Brian G. Feagan, MD FRCP(C)

Professor of Medicine, Epidemiology & Biostatistics
Western University
Senior Scientific Director, Alimentiv Inc.

 

 
Laura Targownik, MD MSHS

Associate Professor, Gastroenterology & Hepatology
University of Toronto
Mount Sinai Hospital

Sunday, November 20, 2022

7:30 am - 8:30 am

Safety of Advanced Therapy Treatment in IBD: What should we consider?

Learning Objectives: 

  1. Review published safety data of advanced IBD therapies
  2. Discuss important considerations regarding the impact of available safety data on clinical care

Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics.  His research focus is the design, conduct and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs.  His research has been devoted to the development, validation and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC.  Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).


Dr. Laura Targownik graduated from the University of Manitoba Medical School in 1997 and completed her residency training in Internal Medicine in 2000. She then went to University of California Los Angeles (UCLA) to complete a 3-year fellowship in Digestive Diseases while also obtaining a Master’s of Science (Health Services) from the UCLA School of Public Health.

Since 2019, Dr. Targownik has been a full-time faculty member at the University of Toronto, where she serves as the Division Director for Gastroenterology & Hepatology. She is currently based at Mount Sinai Hospital, where she provides clinical care and is a clinician-scientist. Prior to joining the faculty at the University of Toronto,  she was the Chief of the Section of Gastroenterology at University of Manitoba, an Associate of the Manitoba Centre for Health Policy and the Associate Director of the IBD Research and Clinical Centre.‚Äč


Sponsored by: